Published on: 25 January 2022 Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA) more
Published on: 24 January 2022 The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months more
125 Years Celebrate Life Learn more about Roche’s 125 year anniversary and the Celebrate Life campaign more
